Accepted for/Published in: JMIR Research Protocols
Date Submitted: Aug 3, 2025
Open Peer Review Period: Aug 4, 2025 - Sep 29, 2025
Date Accepted: Jan 15, 2026
(closed for review but you can still tweet)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Safety of Administration of Vasopressors Through Peripheral Compared to Central Venous Catheters in a Rural Kenyan Hospital: Protocol for a Prospective, Observational Cohort Study
ABSTRACT
Background:
The infusion of vasopressors is a standard treatment for shock, and international guidelines recommend administering these medications through central venous catheters (CVCs) due to concerns for potential extravasation and local tissue injury with peripheral intravenous (PIV) administration. However, CVCs are often unavailable in resource-variable settings due to lack of human and material resources. Previous studies have assessed the safety of vasopressor infusion through PIVs but have considered only limited patient population, a short infusion time, or have used retrospective designs that may have failed to capture mild complications.
Objective:
The primary objective of this study is to observe and describe the incidence of complications among patients receiving vasopressor infusion via PIV. The secondary objective is to assess whether the safety of PIV vasopressor administration via PIVs is non-inferior to the safety of administration via CVC.
Methods:
This prospective, observational study is being conducted at AIC Kijabe Hospital, a 360-bed tertiary care teaching hospital in rural Kenya. All patients (adult, obstetric, pediatric) receiving intravenous vasopressor infusions who are admitted to the intensive care unit or high-dependency unit will be included. Patients will be followed twice daily from the start of vasopressor infusion through 72 hours after vasopressor discontinuation or death, whichever occurs first. Demographic, physiologic, laboratory, therapeutic, and outcome data will be collected.
Results:
Consecutive enrollment began in October 2023 and is ongoing. As of July 2025, we have enrolled 190 patients. We anticipate that the time to enroll the number of patients required to reach our power goal will take 24 months.
Conclusions:
This study in a resource-variable setting will allow for more accurate and comprehensive data collection on vasopressor administration and potential complications as they arise, while most previous studies have been retrospective in nature. In addition, this is the first study of its kind to include both adult and pediatric patients within a mixed-ICU population with broad etiologies of shock, which could improve generalizability.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.